Blend CJC 1295 NO DAC 2MG with Ipamorelin 2MG

Blend CJC-1295 NO DAC with Ipamorelin is a powerful combination of two synthetic peptides: CJC-1295 and ipamorelin. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to the GHRH receptor, stimulating the release of growth hormone. It consists of 30 amino acids with a molecular weight of 3647.16 g/mol. This formulation is CJC-1295 without DAC, meaning it does not contain the drug affinity complex (DAC) used to prolong its half-life.⁽¹⁾

Ipamorelin is a synthetic hexapeptide that stimulates growth hormone release through the growth hormone secretagogue receptor (GHS-R) in the anterior pituitary gland. Although its structure differs from ghrelin, ipamorelin mimics some functions of ghrelin. It consists of 6 amino acids with a molecular weight of 711.39 g/mol.^(2,3) Together, CJC-1295 and ipamorelin enhance growth hormone release by targeting two different receptors, allowing researchers to investigate their synergistic effects.

Scientific in vitro and animal studies have shown that both peptides promote bone health and stimulate insulin release through insulin-like growth factor 1 (IGF-1). Ipamorelin has been associated with significant increases in bone mineral content in animal models, while CJC-1295 supports bone formation by stimulating osteoblast activity through IGF-1.^(4,5) Both peptides have also demonstrated the ability to boost insulin production in pancreatic tissue via IGF-1 mechanisms in animal studies.

Blue Sky Peptide’s Blend CJC-1295 NO DAC with Ipamorelin is available as a white lyophilized powder, with a concentration of 4 mg per vial. This product is intended exclusively for in vitro scientific research and is not for human use or consumption.

All findings referenced here are based on in vitro research or animal models. This product is strictly for laboratory use to explore its biochemical and physiological effects under controlled experimental conditions. Additional studies are necessary to determine its safety and efficacy beyond the research setting.

References:

1. Alba M, Fintini D, Sagazio A, Lawrence B, et al. *Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.* Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-1294.
2. Raun K, Hansen BS, Johansen NL, et al. *Ipamorelin, the first selective growth hormone secretagogue.* Eur J Endocrinol. 1998 Nov;139(5):552-561.
3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. *Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone-releasing peptide, in human volunteers.* Pharm Res. 1999 Sep;16(9):1412-1416.
4. Svensson J, Lall S, Dickson SL, et al. *The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.* J Endocrinol. 2000 Jun;165(3):569-577.
5. Olney RC. *Regulation of bone mass by growth hormone.* Med Pediatr Oncol. 2003;41(3):228-234.